Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review).

ABSTRACT: The benefits of treating several types of cancers using immunotherapy have recently been established. The overexpression of nucleolin (NCL) in a number of types of cancer provides an attractive antigen target for the development of novel anticancer immunotherapeutic treatments. NCL is a multifunctional protein abundantly distributed in the nucleus, cytoplasm and cell membrane. It influences carcinogenesis, and the proliferation, survival and metastasis of cancer cells, leading to cancer progression. Additionally, the meta‑analysis of total and cytoplasmic NCL overexpression indicates a poor prognosis of patients with breast cancer. The AS1411 aptamers currently appear to have therapeutic action in the phase II clinical trial. The authors' research group has recently explored the anticancer

SUBMITTER: Thongchot S 

PROVIDER: S-EPMC10555485 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature